SVG
Commentary
National Review

To Counter China, the US Must Fight Malaria

The administration would do well to treat counter-malaria as a blueprint 鈥� not just for saving lives, but for winning the competition that defines our era.

A health worker displays a bottle containing the vaccine against malaria during the launch of a vaccination campaign for children in Abidjan, C么te d鈥橧voire, on July 15, 2024. (Sia Kambou via Getty Images)
Caption
A health worker displays a bottle containing the vaccine against malaria during the launch of a vaccination campaign for children in Abidjan, C么te d鈥橧voire, on July 15, 2024. (Sia Kambou via Getty Images)

As the United States and the Chinese Communist Party (CCP) struggle in a , Xi Jinping has sent a consistent message to nations caught between Washington and Beijing: You鈥檒l get a better deal with China if you walk away from America. This geopolitical angling is part of a broader return to great-power competition. But the maneuvering didn鈥檛 begin with tariffs. Even before President Donald Trump鈥檚 latest actions, Beijing was quietly approaching third-party nations with a simple pitch: You can鈥檛 trust America. Work with us instead.

The issue at hand was foreign assistance. One of President Trump鈥檚 first moves in his second administration was to restructure U.S. foreign aid. He had good reason. From transgender operas and comic books to DEI musicals, the (USAID) had lost its strategic compass. These programs didn鈥檛 advance American interests, and some actively undermined them.

Beijing saw an opening. From South Asia and the Pacific Islands to Latin America, the CCP stepped in, offering to continue programs disrupted by USAID鈥檚 shake-up. But Xi鈥檚 plan goes far beyond replacing U.S. grants with Chinese loans. He wants to displace American influence.

Washington policymakers must understand: This isn鈥檛 a sideshow to the trade war. Foreign assistance is another front in the new cold war. If the United States wants to win, it must identify what works, double down, and scale up. There are few better examples than America鈥檚 leadership in fighting malaria.

Malaria is one of the world鈥檚 most common and deadly diseases. It strikes rich and poor alike, thriving in urban and rural areas. Spread by infected mosquitoes, it threatens over half the world鈥檚 population. In 2023 alone, there were over 260 million cases and nearly 600,000 deaths. Africa remains hardest hit, accounting for 94 percent of all cases.

The United States has long invested in fighting malaria 鈥� and wisely so. The world鈥檚 deadliest infectious diseases, from Ebola to pandemic flu, often begin with fevers. The same 鈥渉ot spots鈥� where malaria spreads are also 鈥渂lind spots鈥� for emerging pandemics. Treating malaria, in many cases, doubles as an early warning system because testing often reveals other infections in early stages.

More broadly, health crises destabilize societies. Secretary of State Marco Rubio acknowledged this during his Senate confirmation hearing, calling counter-malaria efforts a win-win for America and Africa: 鈥淭he cost benefit of an investment, leveraging private partnerships to deal with things like malaria, pays extraordinary dividends . . . that could be part of an overall approach to Africa . . . improving our prosperity, our security.鈥� He鈥檚 right. Programs that make America safer, stronger, and more prosperous should be the foundation of the Trump administration鈥檚 foreign assistance strategy 鈥� and counter-malaria efforts fill the bill.

Of course, the CCP sees the same opportunity. In recent years, China has expanded its malaria response in Africa, particularly in the Democratic Republic of Congo, the Central African Republic, and Uganda. Between 2000 and 2021, China delivered 279 anti-malaria projects across 36 sub-Saharan countries, totaling nearly $320 million. Since 2015, it鈥檚 also piloted malaria prevention programs in Tanzania.

It may be tempting to view malaria as a rare zone of U.S.-China cooperation. In reality, Beijing uses its so-called Health Silk Road to isolate Taiwan, extract critical resources, and create economic dependencies that ease CCP political 鈥� and, at times, military 鈥� expansion.

Just as one nation will shape the future of global trade, one will also shape the rules of foreign assistance. America must aim to be the first partner of choice. If the Trump administration is serious about overhauling U.S. aid, it should consider malaria efforts a model worth replicating.

Of course, adjustments are in order. The administration could focus on countries of strategic importance 鈥� Nigeria, the Democratic Republic of Congo, and Mozambique, for instance. Compact-like, time-bound programs could be designed to gradually shift financial responsibility from the U.S. to host nations. Malaria-endemic countries already foot more than one-third of the total malaria bill, but they should take on even more of the cost in the future. Partnering with the U.S. International Development Finance Corporation would allow a longer-term transition from aid to investment.

Additionally, the administration should integrate artificial intelligence into counter-malaria work 鈥� not only to fight the disease more efficiently, but to blunt the spread of CCP-controlled AI platforms like DeepSeek. Health tech is becoming a proxy battlefield in this wider struggle for influence.

If the U.S. abandons the field, Beijing won鈥檛 hesitate to fill the vacuum. America can鈥檛 be safer, stronger, or more prosperous without sustaining leadership in this domain. As it reimagines foreign aid, the Trump administration would do well to treat counter-malaria as a blueprint 鈥� not just for saving lives, but for winning the broader competition that defines our era.